Zydus Lifesciences Reports Decline in Q1 Profit Amid Rising Costs
On August 11, Indian pharmaceutical company Zydus Lifesciences announced that its profit for the first quarter dropped nearly 30%. The decline came despite strong sales, largely due to increasing costs.
The company’s consolidated net profit for the quarter ending June 30 fell to 9.40 billion rupees (approximately $98.5 million), compared to last year’s figure of 14.67 billion rupees.
Key Highlights:
-
Many Indian generic drugmakers, including Zydus Lifesciences, rely heavily on the U.S. market for their revenue but are currently facing tough competition, leading to weaker prices.
-
Overall revenue saw a significant rise of 22%, reaching 80.17 billion rupees. However, expenses surged even more quickly, climbing by 41.4%. This increase was driven by a 32% rise in research and development costs and a 47.5% increase in other operating expenses.
-
On a positive note, sales within India grew by 19.5%, totaling 18.16 billion rupees. Additionally, the company’s consumer wellness segment—leveraging popular brands like Glucon D—experienced a remarkable growth of 67.2%, reaching 14.29 billion rupees.
-
Conversely, sales in North America fell by 2.6% to 30.98 billion rupees during the same period.
-
Major competitors like Dr. Reddy’s and Cipla also reported slow U.S. sales for the quarter.
This report is part of a broader trend affecting the pharmaceutical industry, particularly in the face of rising costs and market competition.
